SI9300419B - Benzoksazinoni kot inhibitorji HIV reverzne transkriptaze - Google Patents

Benzoksazinoni kot inhibitorji HIV reverzne transkriptaze Download PDF

Info

Publication number
SI9300419B
SI9300419B SI9300419A SI9300419A SI9300419B SI 9300419 B SI9300419 B SI 9300419B SI 9300419 A SI9300419 A SI 9300419A SI 9300419 A SI9300419 A SI 9300419A SI 9300419 B SI9300419 B SI 9300419B
Authority
SI
Slovenia
Prior art keywords
unsubstituted
chloro
substituted
benzoxazin
dihydro
Prior art date
Application number
SI9300419A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9300419A (en
Inventor
Steven D. Young
Susan F. Britcher
Linda S. Payne
Leknanh O. Tran
William C. Lumma
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9300419(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of SI9300419A publication Critical patent/SI9300419A/sl
Publication of SI9300419B publication Critical patent/SI9300419B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI9300419A 1992-08-07 1993-08-06 Benzoksazinoni kot inhibitorji HIV reverzne transkriptaze SI9300419B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92660792A 1992-08-07 1992-08-07
US5480593A 1993-04-27 1993-04-27

Publications (2)

Publication Number Publication Date
SI9300419A SI9300419A (en) 1994-06-30
SI9300419B true SI9300419B (sl) 2002-10-31

Family

ID=26733517

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300419A SI9300419B (sl) 1992-08-07 1993-08-06 Benzoksazinoni kot inhibitorji HIV reverzne transkriptaze

Country Status (37)

Country Link
EP (1) EP0582455B1 (no)
JP (1) JPH0780860B2 (no)
KR (1) KR100272387B1 (no)
CN (3) CN1051767C (no)
AT (1) ATE197295T1 (no)
AU (1) AU670300B2 (no)
BG (1) BG62612B1 (no)
CA (1) CA2101572C (no)
CZ (1) CZ290447B6 (no)
DE (4) DE69329608T2 (no)
DK (1) DK0582455T3 (no)
DZ (1) DZ1707A1 (no)
ES (1) ES2151897T3 (no)
FI (1) FI115457B (no)
GR (1) GR3034754T3 (no)
HK (1) HK1009267A1 (no)
HR (1) HRP931102B1 (no)
HU (1) HU223076B1 (no)
IL (1) IL106507A (no)
LU (2) LU90709I2 (no)
LV (1) LV12719B (no)
MX (1) MX192812B (no)
MY (1) MY109834A (no)
NL (2) NL300032I2 (no)
NO (3) NO304886B1 (no)
NZ (1) NZ255216A (no)
PL (2) PL176679B1 (no)
PT (1) PT582455E (no)
RO (1) RO113641B1 (no)
RU (1) RU2186775C2 (no)
SG (1) SG52698A1 (no)
SI (1) SI9300419B (no)
SK (1) SK282276B6 (no)
TW (2) TWI233436B (no)
UA (1) UA42699C2 (no)
WO (1) WO1994003440A1 (no)
YU (1) YU49439B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
CA2260922A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
US6147210A (en) 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
SK284935B6 (sk) * 1997-02-05 2006-02-02 Merck & Co., Inc. Forma I (-)-6-chlór-4-cyklopropyletynyl-4-tri-fluórmetyl-1,4- dihydro-2H-3,1-benzoxazín-2-ónu a spôsob jej kryštalizácie
EE9900446A (et) * 1997-04-07 2000-04-17 Dupont Pharmaceuticals Company Bensoksasinoonide asümmeetriline sünteesimine uute vaheühendite kaudu
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
US5952528A (en) * 1997-09-03 1999-09-14 Merck & Co., Inc. Process for enhancing the optical purity
AU744536B2 (en) * 1997-09-03 2002-02-28 Merck Sharp & Dohme Corp. Process for enhancing the optical purity of 2R-(1-hydroxy- 1-trifluoromethyl- 3-cyclopropylpropyn-2YL) -4-chloroaniline
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
EP1091939A1 (en) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2002081456A1 (en) 2001-03-28 2002-10-17 Bristol-Myers Squibb Company Cyanamide, alkoxyamino, and urea derivatives of 4, 4-disubstituted-3, 4-dihydro-2 (1h)- quinazolinones as hiv reverse transcriptase inhibitors
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
US8314094B2 (en) * 2007-10-05 2012-11-20 Msd K.K Benzoxazinone derivative
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
WO2011000532A2 (de) 2009-07-03 2011-01-06 Archimica Gmbh Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
CA3003988C (en) 2010-01-27 2020-01-07 Viiv Healthcare Company Combinations for use in the inhibition of hiv-1
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN102584801B (zh) * 2011-01-06 2015-02-18 中国科学院上海有机化学研究所 Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) * 2011-03-15 2015-02-18 中国科学院上海有机化学研究所 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
WO2020164218A1 (en) 2019-02-15 2020-08-20 Fujian Yongjing Technology Co., Ltd New process for friedel-crafts reaction, and catalyst therefore
CN110372625B (zh) * 2019-08-06 2022-11-01 常州大学 蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) * 2021-04-14 2022-02-18 南京工业大学 一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
WO2023064196A1 (en) * 2021-10-15 2023-04-20 Merck Sharp & Dohme Llc Benzoxazinone derivatives as selective cytotoxic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3562621A (en) * 1967-07-26 1971-02-09 Technipower Inc Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JPH06184124A (ja) 1994-07-05
FI950508A (fi) 1995-02-06
CN1221608A (zh) 1999-07-07
RU95107403A (ru) 1996-11-20
CA2101572C (en) 2001-08-28
CA2101572A1 (en) 1994-02-08
HU9500366D0 (en) 1995-03-28
DE69329608T2 (de) 2001-05-03
HRP931102B1 (en) 2001-06-30
GR3034754T3 (en) 2001-02-28
YU53093A (sh) 1996-10-09
MY109834A (en) 1997-08-30
NL300347I1 (nl) 2008-07-01
FI950508A0 (fi) 1995-02-06
TW382014B (en) 2000-02-11
ES2151897T3 (es) 2001-01-16
NL300032I1 (no) 2001-02-01
SI9300419A (en) 1994-06-30
PL176679B1 (pl) 1999-07-30
AU4449693A (en) 1994-02-10
ATE197295T1 (de) 2000-11-15
WO1994003440A1 (en) 1994-02-17
NL300032I2 (nl) 2001-04-02
BG99383A (bg) 1995-09-29
CZ28695A3 (en) 1995-09-13
EP0582455A1 (en) 1994-02-09
CN1318031C (zh) 2007-05-30
NZ255216A (en) 1996-05-28
PL307348A1 (en) 1995-05-15
NO2000004I1 (no) 2000-06-16
DK0582455T3 (da) 2000-11-27
RU2186775C2 (ru) 2002-08-10
KR950702970A (ko) 1995-08-23
CN1051767C (zh) 2000-04-26
LV12719A (lv) 2001-09-20
MX9304775A (es) 1994-05-31
IL106507A0 (en) 1993-11-15
NO304886B1 (no) 1999-03-01
HK1009267A1 (en) 1999-05-28
EP0582455B1 (en) 2000-11-02
CN1107505C (zh) 2003-05-07
KR100272387B1 (ko) 2000-11-15
SG52698A1 (en) 1998-09-28
DZ1707A1 (fr) 2002-02-17
LU91446I2 (fr) 2008-07-28
IL106507A (en) 1997-11-20
NO950424L (no) 1995-04-06
UA42699C2 (uk) 2001-11-15
TWI233436B (en) 2005-06-01
DE10199013I2 (de) 2007-05-24
CZ290447B6 (cs) 2002-07-17
BG62612B1 (bg) 2000-03-31
CN1250652A (zh) 2000-04-19
LU90709I2 (fr) 2002-02-04
SK16195A3 (en) 1995-07-11
MX192812B (es) 1999-07-30
LV12719B (lv) 2001-12-20
JPH0780860B2 (ja) 1995-08-30
NO950424D0 (no) 1995-02-06
RO113641B1 (ro) 1998-09-30
PT582455E (pt) 2001-03-30
AU670300B2 (en) 1996-07-11
DE10199013I1 (de) 2001-05-23
PL175615B1 (pl) 1999-01-29
DE122008000034I1 (de) 2008-10-02
SK282276B6 (sk) 2002-01-07
HUT71219A (en) 1995-11-28
HRP931102A2 (en) 1997-10-31
YU49439B (sh) 2006-03-03
HU223076B1 (hu) 2004-03-01
NO2008008I1 (no) 2008-06-30
FI115457B (fi) 2005-05-13
DE69329608D1 (de) 2000-12-07
CN1090277A (zh) 1994-08-03

Similar Documents

Publication Publication Date Title
SI9300419B (sl) Benzoksazinoni kot inhibitorji HIV reverzne transkriptaze
BR0009041A (pt) Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
PT98358A (pt) Processo para a preparacao de novos compostos pirazolopiridinicos
PT95389A (pt) Processo para a preparacao de novos derivados pirazolicos com accao anti-inflamatoria
ATE230610T1 (de) Hiv protease hemmer in pharmazeutischen zusammensetzungen zur behandlung von aids
ES2100861T3 (es) Composiciones farmaceuticas para la inhibicion de la reaccion de maillard.
CA2573315A1 (en) Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors
EA199900374A1 (ru) Ингибитор вторичной катаракты
EP1219605A4 (en) UREA COMPOUNDS, PROCESS FOR PRODUCING AND USING THE SAME
DE69308406D1 (de) Thiadiazol-Derivate zur Behandlung von depressiven Zuständen

Legal Events

Date Code Title Description
IF Valid on the event date
SP73 Change of data on owner

Owner name: MERCK SHARP & DOHME CORP.; US

Effective date: 20100329

SP73 Change of data on owner

Owner name: MERCK SHARP & DOHME CORP.; US

Effective date: 20121204